Cytomyx Holdings to acquire Clinomics Biosciences
UK biotech company Cytomyx Holdings, of Cambridge, has agreed to acquire US-based Clinomics Biosciences.
UK biotech company Cytomyx Holdings, of Cambridge, has agreed to acquire US-based Clinomics Biosciences.
Clinomics has pioneered the development of an emerging high throughput biology screening technology known as Tissue MicroArrays that enables researchers to study hundreds of individual tissue samples simultaneously in parallel to establish the relative levels of protein expression in those samples and thereby draw conclusions as to the relevance of a protein target to a specific disease.
'We are extremely pleased to achieve this agreement with Cytomyx,' said Steve Turner, ceo of Clinomics Biosciences. 'I believe both companies will benefit greatly from our combined operations and seamless access to the global life sciences market.'